US lab operator Quest Diagnostics to launch bird flu test at end of October
Oct 23 -Lab operator Quest Diagnostics DGX.N said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S. Centers for Disease Control and Prevention (CDC) gave it contracts to support testing for two emerging infectious diseases, including the Oropouche virus.
WHY IT'S IMPORTANT
The spread of bird flu among dairy herds and infections of 27 people this year have alarmed some public health experts.
More than 100 million U.S. chickens, turkeys and other birds have been eliminated by the virus since the outbreak began in 2022.
The CDC says that this year, there have been 91 cases of the Oropouche virus, which spreads primarily through bites from midges as well as from some mosquitoes.
Last month, the CDC issued a health alert to notify clinicians and public health authorities of an increase in Oropouche virus cases in the Americas region that has caused two deaths so far this year.
CONTEXT
Besides Quest, the CDC is working with four laboratory companies, including Aegis, ARUP, Ginkgo BioWorks DNA.N and Labcorp LH.N, to develop tests for health outbreaks.
This will support the country's preparedness for these threats by ensuring a commercial laboratory provider is able to supplement public health laboratories in case of an outbreak in people.
The CDC contract also provides Quest with funds to maintain testing readiness, such as for adequate supplies of equipment and chemical reagents used to perform the tests.
WHAT'S NEXT
Quest's bird flu test will be available with a prescription.
Its laboratory in San Juan Capistrano, California, which developed the test, will also conduct the test.
The test is intended to be performed using respiratory specimens or specimens of the outer membrane of eyes collected from people suspected of having the virus, or who meet the CDC's testing criteria.
Reporting by Puyaan Singh in Bengaluru; Editing by Savio D'Souza
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
